IMR Press / EJGO / Volume 29 / Issue 2 / pii/1630995392570-1555646843

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Original Research
Estrogen receptor α and β expression in a case matched series of serous and endometrioid adenocarcinomas of the ovary
Show Less
1 Indiana Women’s Oncology, St. Vincent Hospitals Indianapolis, TN University of Iowa Hospitals and Clinics, Holden Comprehensive Cancer Center, Division of Gynecologic Oncology, Iowa City, IA (USA)
Eur. J. Gynaecol. Oncol. 2008, 29(2), 126–128;
Published: 10 April 2008

Objective: The purpose of this study was to analyze estrogen receptor α and β (ERα, ERβ) expression in a stage and grade matched cohort of patients with serous and endometrioid adenocarcinoma of the ovary. Methods: Forty-two patients from 1991 to the present were found to have the diagnosis of endometrioid adenocarcinoma of the ovary and have tissue available for analysis. Of these 42, ten were selected for analysis. These were stage and grade matched with ten patients having serous adenocarcinoma of the ovary during the same time period. ERα and ERβ mRNA was detected by a multiplex RT-PCR and amplification of random hexamer generated cDNA using a housekeeping gene (G3PD) as a control for mRNA quality and quantity. Methylation specific PCR (MS-PCR) was used to correlate methylation of the ERα and ERβ CpG islands with mRNA expression status. Results: ERα expression was present in ten of ten endometrioid adenocarcinomas but in only five of ten serous carcinomas (χ2, p = 0.01). ERβ expression was present in six of ten endometrioid adenocarcinomas and in four of ten serous caricinomas (χ2, p = 0.65). Methylation of the ERα and ERβ CpG islands was found in tumors without mRNA expression but not in the tumors with mRNA expression (p = 0.005). Conclusions: ERα expression, but not ERβ expression, is significantly more common in endometrioid than serous adenocarcinomas of the ovary when controlled for stage and grade. The role of methylation in ER silencing may lead to potential therapeutic interventions.
Estrogen receptor
Ovarian cancer
Back to top